BUZZ-Johnson & Johnson falls after talc litigation overshadows 2026 profit forecast

Reuters01-21 21:07
BUZZ-Johnson & Johnson falls after talc litigation overshadows 2026 profit forecast   

** Shares of healthcare conglomerate Johnson & Johnson JNJ.N fall 2.5% to $212.80 premarket

** On Tuesday, a court-appointed special master recommended that expert testimony linking the company's talc products to ovarian cancer be allowed in court

** J&J has been fighting claims over its talc products in both federal and state court for years, and has maintained that its products are safe and do not cause cancer

** "The talc litigation concerns may be driving the stock down slightly in pre-market trading," RBC Capital Markets analysts wrote in a note

** Co forecasts 2026 adj. profit in the range of $11.43 and $11.63 per share, beating analysts' estimate of $11.45 per share, according to data compiled by LSEG

** Co posts Q4 adj. profit of $2.46 per share, compared with analysts' estimate of $2.44 per share

** Reports Q4 revenue of $24.56 billion, beating estimates of $24.16 billion

** JNJ stock climbed 43.1% in 2025

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment